Chen Weisan, Masterman Kelly-Anne, Basta Sameh, Haeryfar S M Mansour, Dimopoulos Nektaria, Knowles Barbara, Bennink Jack R, Yewdell Jonathan W
T Cell Laboratory, Cancer Vaccine Unit, Ludwig Institute for Cancer Research, Austin & Repatriation Medical Centre, Heidelberg, Australia.
Eur J Immunol. 2004 Jan;34(1):194-9. doi: 10.1002/eji.200324257.
"Cross-priming" refers to the activation of naive CD8+ T cells by antigen-presenting cells that have acquired nominal antigens from another cell. The biological relevance of cross-priming of CD8+ T cells has recently been challenged (Zinkernagel, R. M., Eur. J. Immunol. 2002. 32: 2385-2392), on the basis that responses are weak or poorly quantitated, and the determinants recognized are undefined. Here we show that cross-priming is a robust process that elicits vigorous primary responses to multiple peptides in two well-defined systems. Our findings support the relevance of cross-priming in CD8+ T cell responses to viruses and tumor cells, and demonstrate that cross-priming elicits CD8+ T cells to determinants generated by the endogenous processing pathway.
“交叉呈递”是指由从另一个细胞获取了名义抗原的抗原呈递细胞激活初始CD8⁺T细胞。最近，CD8⁺T细胞交叉呈递的生物学相关性受到了挑战（津克纳格尔，R.M.，《欧洲免疫学杂志》，2002年。32：2385 - 2392），理由是反应较弱或难以定量，且所识别的决定簇尚不明确。在此我们表明，交叉呈递是一个强大的过程，在两个明确的系统中能引发对多种肽段的强烈初始反应。我们的研究结果支持交叉呈递在CD8⁺T细胞对病毒和肿瘤细胞反应中的相关性，并证明交叉呈递能使CD8⁺T细胞针对内源性加工途径产生的决定簇产生反应。
